For section 4.4, the CHMP implemented a revised wording for the hyperprolactinaemia section, excluding specific mention of prolactinoma and breast cancer, as although data supporting a possible relationship between hyperprolactinaemia and risk of some prolactin-dependent tumours exists, the data is still largely inconclusive from a clinical perspective.